Table 2. Correlation analysis of covariates and therapeutic efficacy of denosumab.

Covariates	Lumbar spine				Total hip				Femur neck
	T-score difference		aBMD change (%)		T-score difference		aBMD change (%)		T-score difference		aBMD change (%)
	r	P value	r	P value	r	P value	r	P value	r	P value	r	P value
Age, years	0.072	0.360	0.079	0.322	0.127	0.110	0.116	0.143	0.031	0.751	0.025	0.804
Postmenopause	0.003	0.970	0.022	0.784	0.107	0.184	0.096	0.233	0.015	0.885	0.010	0.920
BMI, kg/m2	0.029	0.730	0.018	0.830	0.013	0.880	−0.051	0.540	0.190	0.064	0.210	0.041*
Duration of SLE, years	−0.028	0.725	−0.010	0.901	0.047	0.551	0.020	0.804	0.016	0.872	0.048	0.629
SLEDAI-2K score	−0.228	0.003**	−0.240	0.002**	−0.129	0.105	−0.068	0.394	−0.202	0.039*	−0.255	0.009**
Calcium, mg/dL	0.122	0.136	0.139	0.090	0.100	0.223	0.074	0.369	0.124	0.224	0.160	0.117
25-Hydroxyvitamin D, ng/mL	−0.169	0.057	−0.169	0.059	−0.008	0.933	0.014	0.878	0.006	0.955	0.009	0.935
Cumulative GC, mg	−0.096	0.224	−0.096	0.227	0.086	0.280	0.049	0.538	0.065	0.508	0.040	0.686
Concurrent GC, mg	−0.143	0.069	−0.154	0.051	−0.089	0.263	−0.040	0.614	−0.079	0.421	−0.116	0.241
Hydroxychloroquine use	0.021	0.791	0.010	0.897	−0.010	0.903	0.047	0.556	−0.209	0.032*	−0.220	0.025*
Prior osteoporosis treatment	−0.211	0.007**	−0.213	0.007**	−0.029	0.720	−0.004	0.962	−0.072	0.463	−0.077	0.438
CTx, ng/mL	0.329	0.017*	0.356	0.010*	0.260	0.065	0.279	0.047*	0.040	0.831	0.034	0.857
P1NP, ng/mL	0.409	0.362	0.363	0.424	0.257	0.578	−0.290	0.528	0.676	0.095	0.262	0.571
Baseline BMD value	−0.320	0.000**	−0.319	0.000**	−0.210	0.008**	−0.266	0.001**	−0.079	0.423	−0.131	0.184

Baseline BMD value: T-score or aBMD value at denosumab initiation for the respective site.

*P<0.05, **P<0.01.

aBMDareal bone mineral densityBMDbone mineral densityBMIbody mass indexCTxc-telopeptide of collagen type 1GCglucocorticoidP1NPprocollagen 1 N-terminal propeptideSLEDAI-2KSLE Disease Activity Index 2000